Pfizer "COVID-19 Vaccine Shows 95% Efficacy" Final Clinical Results
On May 24th (local time), a participant in a vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, Maryland, USA, is preparing to receive the novel coronavirus disease (COVID-19) vaccine candidate 'BNT162b2,' jointly developed by the American pharmaceutical company Pfizer and the German company BioNTech.
American pharmaceutical company Pfizer announced that the final results showed a 95% efficacy rate for its novel coronavirus (COVID-19) vaccine, AFP reported on the 18th (local time).
On the 9th, Pfizer had announced that an analysis of 94 participants in the Phase 3 clinical trial of the COVID-19 vaccine, developed jointly with German company BioNTech, showed an efficacy rate exceeding 90%.
A week later, on the 16th, American pharmaceutical company Moderna announced interim results showing a 94.5% efficacy rate for its COVID-19 vaccine candidate.
Pfizer's announcement of the final results came just two days after Moderna's announcement.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- [New York Stock Exchange] Major Indexes Close Up Over 1% as Treasury Yields and Oil Prices Fall
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
With vaccine candidates consecutively showing high efficacy rates, expectations are growing that widespread vaccine distribution will be possible.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
